다우존스 지수

같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.

등록

AFMD

Affimed NV (AFMD)

Affimed NV

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:AFMD

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/06/02	02:02	GlobeNewswire Inc.	Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort	NASDAQ:AFMD	Affimed NV
2024/05/29	19:30	GlobeNewswire Inc.	Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung Cancer	NASDAQ:AFMD	Affimed NV
2024/05/28	19:51	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:AFMD	Affimed NV
2024/05/28	19:30	GlobeNewswire Inc.	Affimed Announces Annual General Meeting of Shareholders	NASDAQ:AFMD	Affimed NV
2024/05/24	06:22	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:AFMD	Affimed NV
2024/05/24	06:05	GlobeNewswire Inc.	Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024	NASDAQ:AFMD	Affimed NV
2024/05/14	23:05	GlobeNewswire Inc.	Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 Congress	NASDAQ:AFMD	Affimed NV
2024/04/24	17:05	GlobeNewswire Inc.	Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology	NASDAQ:AFMD	Affimed NV
2024/03/28	19:30	GlobeNewswire Inc.	Affimed Reports 2023 Financial Results and Operational Progress	NASDAQ:AFMD	Affimed NV
2024/03/21	19:30	GlobeNewswire Inc.	Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024	NASDAQ:AFMD	Affimed NV
2024/03/12	05:05	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:AFMD	Affimed NV
2024/03/06	20:34	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:AFMD	Affimed NV
2024/03/06	20:30	GlobeNewswire Inc.	Affimed Announces 1-for-10 Reverse Stock Split	NASDAQ:AFMD	Affimed NV
2024/01/09	06:45	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:AFMD	Affimed NV
2024/01/09	06:05	GlobeNewswire Inc.	Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer	NASDAQ:AFMD	Affimed NV
2024/01/08	22:11	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:AFMD	Affimed NV
2024/01/08	22:00	GlobeNewswire Inc.	Affimed Announces Leadership Change and Organizational Restructuring	NASDAQ:AFMD	Affimed NV
2024/01/03	20:30	GlobeNewswire Inc.	Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck	NASDAQ:AFMD	Affimed NV
2023/12/11	20:10	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:AFMD	Affimed NV
2023/12/11	20:02	GlobeNewswire Inc.	Affimed Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-treated EGFR-Wildtype Non-Small Cell Lung Cancer Patients	NASDAQ:AFMD	Affimed NV
2023/12/11	20:00	GlobeNewswire Inc.	Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)	NASDAQ:AFMD	Affimed NV
2023/12/04	20:30	GlobeNewswire Inc.	Affimed to Host Investor Conference Call Highlighting Clinical Data for Acimtamig (AFM13) and AFM24	NASDAQ:AFMD	Affimed NV
2023/11/30	21:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:AFMD	Affimed NV
2023/11/14	20:30	GlobeNewswire Inc.	Affimed Reports Third Quarter 2023 Financial Results and Highlights Operational Progress	NASDAQ:AFMD	Affimed NV
2023/11/09	20:30	GlobeNewswire Inc.	Affimed Announces Acimtamig as International Nonproprietary Name for AFM13	NASDAQ:AFMD	Affimed NV
2023/11/07	20:30	GlobeNewswire Inc.	Affimed to Report Third Quarter 2023 Financial Results & Corporate Update on November 14, 2023	NASDAQ:AFMD	Affimed NV
2023/11/04	01:05	GlobeNewswire Inc.	Affimed Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types at the 38th Annual Meeting of the Society for Immunotherapy of Cancer	NASDAQ:AFMD	Affimed NV
2023/11/02	22:05	GlobeNewswire Inc.	Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting	NASDAQ:AFMD	Affimed NV
2023/11/01	19:30	GlobeNewswire Inc.	Affimed to Participate in Upcoming Investor Conferences	NASDAQ:AFMD	Affimed NV
2023/10/04	19:40	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:AFMD	Affimed NV

검색 관련기사 보기:NASDAQ:AFMD

1 2 3 4 5 6 7 8 9 10 다음 >>

Dr Martens (PK)

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관